Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …

Simple Summary There is a pressing need for new effective treatments against glioma. A
promising option is a class of drugs called poly (ADP-Ribose) polymerase (PARP) inhibitors …

The morbidity associated with pediatric medulloblastoma, in particular in patients who
develop leptomeningeal metastases, remains high in the absence of effective therapies …

Simple Summary Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-
I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The …

Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB)
penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in …

Recent studies demonstrated that pyroptosis plays a crucial role in shaping the tumor-
immune microenvironment. However, the influence of pyroptosis on lower-grade glioma …

Faced with unique immunobiology and marked heterogeneity, treatment strategies for
glioblastoma require therapeutic approaches that diverge from conventional oncological …

Glioblastoma (GBM) is a highly malignant brain tumor with a dismal prognosis. Standard
therapy for GBM comprises surgical resection, followed by radiotherapy plus concomitant …

A glioblastoma (GBM) is one of the most aggressive, infiltrative, and treatment-resistant
malignancies of the central nervous system (CNS). The current standard of care for GBMs …

Background Despite the putatively targetable genomic landscape of high-grade gliomas, the
long-term survival benefit of genomically-tailored targeted therapies remains discouraging …